Integrating a drug with a mechanical device can, in some cases, improve patient outcomes and boost sales. But manufacturing these products is no simple feat: It often requires a specialized contract manufacturer with extensive experience in the field to make a drug-device combo buildable and scalable. There’s a lot to consider when manufacturing a medical […]
Drug-Device Combinations
BioTime lands $2m for dry-AMD therapy
BioTime Inc. (NYSE:BTX) said today that its subsidiary, Cell Cure Neurosciences, has landed a $2 million grant from the Israel Innovation Authority for the development of its dry-AMD therapy, OpRegen. The Alameda, Calif.-based company’s OpRegen is an investigational therapy that delivers retinal pigment epithelial cells into the subretinal space to replace lost RPE cells. “This new […]
Ophthotech eye-drug trial fails to meet primary endpoint
Shares in Ophthotech (NSDQ:OPHT) dipped to $2.46 apiece this morning after the company announced that its Phase III wet age-related macular degeneration trial failed to meet its primary endpoint. The New York-based company said that the addition of Fovista (pegpleranib) to Eylea or Avastin, both anti-VEGF therapies, did not significantly improve visual acuity after 12-months compared […]
Medtronic launches DAPT study for Resolute Onyx DES
Medtronic (NYSE:MDT) said today that it’s launching a study of dual anti-platelet therapy and its Resolute Onyx drug-eluting stent. The 2,000-patient study is designed to compare a one-month course of aspirin and an anti-coagulant in conjunction with the Resolute Onyx device or the BioFreedom DES made by Biosensors International (PINK:BSNRY). The Resolute Onyx stent is made […]
Pavmed beats Q2 EPS by a penny
Medical device maker Pavmed Inc. (NSDQ:PAVM) topped expectations on Wall Street with its second quarter results today. The New York-based company posted a net loss of -$989,707, or -8¢ per share, for the 3 months ended June 30, for bottom-line growth of 25% compared with the same period last year. Adjusted to exclude 1-time items, earnings per […]
SteadyMed tops Q2 sales estimates
Shares in SteadyMed (NSDQ:STDY) fell today after the pharmaceutical company beat sales expectations on Wall Street with its second quarter results, but missed EPS estimates. The San Ramon, Calif.-based company posted a net loss of -$8.1 million on sales of $319,000 for the 3 months ended June 30, for bottom-line loss of -14% on sales growth […]
Cytori Therapeutics posts mixed Q2
Shares in Cytori Therapeutics (NSDQ:CYTX) fell today after the biotech missed sales expectations on Wall Street with its second quarter results, but topped EPS estimates. The San Diego, Calif.-based company posted a net loss of -$6 million on sales of $1.5 million for the 3 months ended June 30, for bottom-line growth of 6% on sales […]
MIT researchers developing device to pump drugs to the brain
Researchers at the Massachusetts Institute of Technology are developing a pump to deliver drugs directly to the brain. Alejandro Aponte, a mechanical engineering major at the University of Puerto Rico, has spent his summer working with Michael Cima, a professor of engineering, as part of MIT’s Summer Scholars program. The team’s pump prototype is attached […]
IntelGenx misses Q2 sales, earnings estimates
Drug delivery company IntelGenx (CVE:IGX) missed expectations on Wall Street yesterday with its second quarter results. The Quebec-based company posted a net loss of -$550,000 on sales of $1.1 million for the 3 months ended June 30, paring its losses by 32% on sales growth of 64% compared with the same period last year. Adjusted […]
Titan Pharmaceuticals misses estimates in Q2
Shares in Titan Pharmaceuticals (NSDQ:TTNP) fell yesterday after the pharmaceutical company missed expectations on Wall Street with its second quarter results. The San Francisco, Calif.-based company posted a net loss of -$3.5 million on sales of $77,000 for the 3 months ended June 30. In the same period last year, Titan posted profits of $11.9 million […]